Geneva Advisors’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$1.87M Buy
21,059
+201
+1% +$16.9K 0.03% 235
2017
Q1
$1.68M Sell
20,858
-1,116
-5% -$87.2K 0.03% 248
2016
Q4
$1.56M Sell
21,974
-446
-2% -$35K 0.03% 247
2016
Q3
$1.94M Sell
22,420
-7
-0% -$610 0.04% 205
2016
Q2
$1.95M Buy
22,427
+190
+0.9% +$15.4K 0.04% 199
2016
Q1
$1.67M Buy
22,237
+593
+3% +$44.7K 0.03% 218
2015
Q4
$1.67M Sell
21,644
-236
-1% -$17.8K 0.03% 226
2015
Q3
$1.47M Buy
21,880
+269
+1% +$19.8K 0.03% 241
2015
Q2
$1.6M Buy
21,611
+6,820
+46% +$521K 0.03% 234
2015
Q1
$1.15M Buy
14,791
+2,198
+17% +$167K 0.02% 276
2014
Q4
$909K Sell
12,593
-1,467
-10% -$102K 0.02% 313
2014
Q3
$871K Buy
14,060
+843
+6% +$53.6K 0.02% 332
2014
Q2
$843K Buy
13,217
+4,147
+46% +$252K 0.02% 340
2014
Q1
$558K Buy
9,070
+66
+0.7% +$3.84K 0.01% 370
2013
Q4
$517K Buy
9,004
+109
+1% +$6.18K 0.01% 329
2013
Q3
$474K Sell
8,895
-373
-4% -$20.1K 0.01% 343
2013
Q2
$477K Buy
+9,268
New +$458K 0.01% 287

Other funds holding MDT

Geneva Advisors's MDT Position: Q2 2017 in Review

Geneva Advisors increased its Medtronic (MDT) stake by 0.96% in Q2 2017, buying an estimated $16.9K and bringing the position to 21,059 shares worth $1.87M. The position accounts for 0.03% of the portfolio, ranked #235.

Geneva Advisors first reported a position in MDT in Q2 2013 and has held it in 17 quarters since. The position peaked at $1.95M in Q2 2016. 1,281 funds tracked by Wall St. Rank hold MDT as of Q2 2017.

  • Geneva Advisors held 21,059 shares of Medtronic worth $1.87M as of Q2 2017.
  • Geneva Advisors bought 201 Medtronic shares in Q2 2017, an estimated $16.9K.
  • Medtronic made up 0.03% of Geneva Advisors's portfolio in Q2 2017, its #235 holding.
  • Geneva Advisors first reported a position in Medtronic in Q2 2013 and has held it in 17 quarters since.
  • Geneva Advisors's Medtronic position peaked at $1.95M in Q2 2016.
  • 1,281 funds tracked by Wall St. Rank held Medtronic as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.